While several studies, such as AWARD 10, Duration 8, and AGATE, have looked at the combined use of SGLT2 and GLP-1 receptor agonists in T2D patients, there have not yet been any studies specifically focused on the effectiveness of this combination for MASH treatment [147]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.